ImmunoGen Message Board - Msg: 28782703

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	3/17/2013 1:42:14 AM
	Read Replies (1) of 5665

It's my belief that by the time ASCO's over it will be clear that at least a few of IMGN's pipeline products are producing results worthy ultimately of Phase III Trials if in fact they're not doing registrational trials at lower levels. While Phase III isn't a guarantee of approval, roughly 70% of the drugs that enter Phase III are eventually approved. The following link provides access to data on NDA approvals: siliconinvestor.com It seems that just over half are approved on initial application, and many take several filings but ultimately the greater majority are approved. What's sad is that years are wasted as the drug is in no way improved during the time the FDA demands more. Drugs should be approved faster, but all should have all results tracked indefinitely, and all results should be available to all, no settlements for poor outcomes should be permitted to be hidden. This certainly would be fought by the legal establishment, but costs would greatly go down and nuisance suits would essentially disappear as companies won't settle if the settlement goes on the record. As always, JMHO. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next